CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to …
Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »
I’ve been more interested in histones and their modifications versus DNA methylation when it comes to epigenetics and chromatin. In part this has just been because I have studied histones so much more. For example, we have been knocking out the two histone variant H3.3 genes, H3f3a and H3f3b, now for a decade. My lab also …
Weekly reads: DNA methylation, H3 K27M in glioma, memory wipe, teeth Read More »
Who is David Sinclair and why is he all over the media related to anti-aging efforts? This post is my effort to fact-check Sinclair’s statements in the context of the broader rejuvenation arena. In the process I also review his most recent paper from my view as a stem cell and cancer biologist interested in …
Review of new David Sinclair paper, supplements & anti-aging glitz Read More »
Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might …
Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »
The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had …
Weekly reads: Sarepta, epigenomics, FDA on eyedrops Read More »
There has been a big jump in paper retractions in science over the last 20 years. What’s going on? How do the trends in the stem cell field compare to other fields like cancer research and more broadly? Is AI going to change the dynamic between those engaging in misconduct and those who are looking for misconduct …
Trends in retractions as AI arms race on misconduct looms Read More »
I wrote earlier this week about genome sequencing of famous dead celebrities, pointing out that the trend seems full of ethical complexities. Genome news More broadly, sequencing the genomes of non-celebrities from hundreds or thousands of years ago can be important research. A new NYT piece covers such work on the Swahili people. Such research …
Weekly reads: genome sequencing, chemical reprogramming 2.0 Read More »
About twenty years ago a science story made big news of a so-called anti-aging Methuselah gene. Methuselah gene and anti-aging The claim was that this DNA conferred long life on people. Hence the name Methuselah, which refers to a man from the Bible who reportedly lived 969 years. The so-called Methuselah gene was at first not a …
Perspectives on David Sinclair anti-aging Cell pub & in vivo reprogramming Read More »
Near-billionaire Bryan Johnson apparently does not like getting old and he’s trying to do something transformative about it. He and his team are experimenting in a big way. As a 55-year-old myself, I can’t blame him for wanting to fight aging in general. However, his anti-aging project includes some extreme stuff. Will some in the …
Skepticism on the Bryan Johnson anti-aging extravaganza Read More »
Let’s start with a couple of new pieces on in vivo reprogramming. The idea here is to do something like making iPS cells but doing it inside organisms and not quite pushing cells all the way back to pluripotency. Just younger, healthier cells. Why do that? The goal is to achieve a kind of anti-aging …
Weekly reads: reprogramming aging, astrocytes, cartilage, ChatGPT Read More »